|
 |
| Ex Vivo Metrics™: How Drug Studies in Reanimated Human Organs Could Revitalize the Drug Development Process
An editorial by Gerald Curtis, PhD
Fallout from the catastrophic phase I clinical trial of TeGenero’s monoclonal antibody TGN1412 in March 2006,1 in which 6 volunteers suffered life-threatening “cytokine storms,” includes newly tightened regulations in the United Kingdom and renewed concern worldwide about first-in-human trials, particularly for compounds with novel targets or mechanisms of action.
Read
more - More
Editorials
|
 |
| DNA
Genotyping from human FFPE Samples |
|
In this feasibility study, Applied Biosystems demonstrates how the combined
use Recover All Total Nucleic |
|
Acid Isolation Kit and TaqMan SNP Genotyping
Assay can result in high quality, reproducible, and reliable genotyping
data.. Read
more |
|
 |
Millipore has
launched the CellCiphr Cytotoxicity Profiling Assay Kit
using human HepG2 cells. This assay panel detects
drug-induced hepatotoxicity and is expected to be used
early in the drug discovery process. read
more
Cartesian Gridspeed, Ltd. announced the
opening of its new sales, marketing and technical support
subsidiary, SLIM Search, Inc. in Mission Viejo,
California. SLIM
Search, Inc. is marketing
its SLIM Search genomic search tool to universities,
government research, and research and development
departments of biotechnology corporations and individual
contributors. read
more
The new Variant Reporter Software from Applied
Biosystems automates detection of variants and
streamlines data analysis process. The software uses
proprietary algorithms to identify genetic variations
based on standardized or user-defined parameters. Results
are presented for validation in a visual format that
allows researchers to simultaneously compare multiple
quality control metrics. More information and a free trial
version are available at:
read
more
More
Products
|
 |
| We invite your comments and feedback for this edition of Biomarker Breakthroughs. Email us at
maloryea@gmail.com |
| |
|
|
DNA Array Analyzing Copy Number Variation (CNV) Launched by Illumina
In collaboration with deCODE genetics, Illumna, launched a new DNA Analysis BeadChip called the HumanCNV370-Duo -- the world's first microarray designed to specifically target novel regions of the genome that show copy number variation (CNV). DNA copy number variation has already been linked to cancers, congenital disorders, and other common diseases. The HumanCNV370-Duo will allow researchers to increase the number of samples analyzed, while maintaining unprecedented data quality. Powered by Illumina's Infinium Assay, the HumanCNV370-Duo enables researchers to analyze two samples simultaneously and access novel content for detecting disease-relevant CNV regions. Content found on this BeadChip will also be available on Illumina's Human 1M, a single-chip solution that will profile over one million diverse genetic variants. For more information,
see press release and this
white
paper.
Launching a new product?
Send new product announcements to maloryea@gmail.com.
In your e-mail please indicate why your announcement is relevant to readers of Biomarker Breakthroughs.
3-21- 07 - Biomarker Breakthroughs
|
|
|
